查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1541673

2024-2032 年按疫苗类型（四价、三价）、技术（基于鸡蛋、基于细胞）、年龄组（儿童、成人）、给药途径（注射、鼻喷雾）和地区分類的流感疫苗市场报告

Influenza Vaccine Market Report by Vaccine Type (Quadrivalent, Trivalent), Technology (Egg-based, Cell-based), Age Group (Pediatric, Adult), Route of Administration (Injection, Nasal Spray), and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 138 Pages | 商品交期: 2-3个工作天内

价格

IMARC Group年全球流感疫苗市场规模达67亿美元。政府机构推出了许多促进疫苗接种计划的有利倡议、流感和季节性爆发流行率的上升以及更有效和保护范围更广的流感疫苗的推出是推动全球市场的一些关键因素。

全球流感疫苗市场分析：

主要市场驱动因素：流感疫苗市场的主要驱动因素之一是医疗保健组织为提高公众对流感疫苗接种重要性的认识而发起的越来越多的倡议。这些机构也组织健康教育活动，推动市场成长。此外，各国政府机构正在为老年人、医护人员和儿童等优先年龄层提供补贴和免费疫苗接种，这反过来又改善了获得疫苗的机会。

主要市场趋势：流感疫苗市场的主要趋势之一是主要参与者对四价疫苗生产和分销的投资不断增加。此外，重组和细胞方法等新技术的引入预计将在预测期内提振流感疫苗市场需求。

地理趋势：根据报告，北美拥有最大的流感疫苗区域市场。医疗保健当局越来越注重优先考虑疫苗接种计划和活动，这正在推动区域市场的发展。此外，北美完善的医疗基础设施和对研发活动的广泛投资也是重要的成长诱导因素。

竞争格局：流感疫苗市场的一些知名公司包括雅培实验室、阿斯特捷利康公司、CSL Limited、第一三共有限公司、Emergent BioSolutions Inc.、F. Hoffmann-La Roche AG、Gamma Vaccines Pty Ltd、葛兰素史克公司、默克公司& Co. Inc.、诺华公司、辉瑞公司、赛诺菲和 SINOVAC 等。

挑战与机会：流感疫苗市场前景的主要挑战之一是复杂的监管审批流程，这可能会对疫苗的分配产生负面影响。除此之外，扩大生产规模和确保各年龄层的功效和安全性的需求不断增长，进一步阻碍了全球市场。然而，政府机构和公共卫生机构为确保流感疫苗易于获得、有效并被个人接受而做出的持续努力将在未来几年继续促进流感疫苗市场的成长。

全球流感疫苗市场趋势：

季节性流感爆发和流行病的增加

季节性流感病例的增加导致住院率上升。例如，根据 Statista Research 2023 年 12 月 6 日发布的报告，2022-2023 年流感季节美国有 3,100 万流感病例。此外，2021-2022年流感季节期间，共有4,977人因流感死亡。除此之外，美国很大一部分人口未能接种疫苗。 2021-2022年，18-49岁族群中只有37%接种了流感疫苗，比例远低于儿童和老年人。因此，医疗保健组织越来越重视流感疫苗接种的重要性，这正在促进市场成长。例如，2023年2月，世界卫生组织（WHO）公布了2023-2024年流感季节流感疫苗病毒成分的建议。这项消息是在为期 4 天的流感病毒疫苗成分会议结束时的资讯发布会上宣布的。

对流感疫苗接种的意识不断增强

季节性流感的日益普及主要推动了市场的成长。例如，2022年2月发布的全球流感资料提到，全球估计有10亿人感染季节性流感。与此一致的是，报告也指出，在这10亿人中，每年约有3至500万人罹患严重流感。此外，根据世界卫生组织2022年12月公布的资料，欧洲地区有5%-15%的人口受到流感影响。同样，Plos One Journal 2021 年 7 月发表的文章提到，每年约有 5%-10% 和 20%-30% 的新流感感染病例发生在儿童和成人身上。流感病毒病例的增加正在提高人们对流感疫苗接种的认识，这为整体市场成长提供了积极的前景。除此之外，医疗保健组织正在发起活动，提供有关免疫接种益处的信息，从而推动对流感疫苗的需求。例如，赛诺菲于2022 年6 月进行的一项医疗保健调查报告称，药剂师和医生建议疾病管制与预防中心(CDC) 为65 岁及以上的人群提供Fluzone 高剂量四价疫苗等疫苗，用于治疗流感。所有年龄层的个人日益增长的倾向将在预测期内继续推动流感疫苗的市场份额。

政府机构日益增长的支持

全球各地的政府机构正在与主要公司合作，以支持与流感疫苗开发相关的研发活动。根据流感疫苗市场统计，2021年9月，美国疾病管制与预防中心（CDC）建立了由生物医学高级研究与开发局（BARDA）协调的广泛的机构间合作伙伴关係，支持新型流感疫苗的高级开发。此外，政府当局正在加强和放宽监管审批流程，这对流感疫苗市场的成长产生了积极影响。例如，2022年7月，美国FDA批准了葛兰素史克生产四价疫苗Fluarix的请求。与此相适应，政府也投资与流感疫苗开发相关的临床试验和研发活动。例如，2022年3月，澳洲政府机构投资超过1亿美元购买季节性流感疫苗，以保护处于危险中的个人。此外，主要医疗保健公司正在广泛投资以疫苗形式引入先进疗法。这反过来又支撑了流感疫苗市场的未来。

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 数据来源
    • 主要来源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球流感疫苗市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依疫苗类型

  • 四价
    • 市场趋势
    • 市场预测
  • 三价
    • 市场趋势
    • 市场预测

第 7 章：市场区隔：依技术

  • 以鸡蛋为主
    • 市场趋势
    • 市场预测
  • 基于细胞的
    • 市场趋势
    • 市场预测

第 8 章：市场区隔：依年龄段

  • 儿科
    • 市场趋势
    • 市场预测
  • 成人
    • 市场趋势
    • 市场预测

第 9 章：市场区隔：依管理途径

  • 注射
    • 市场趋势
    • 市场预测
  • 鼻喷剂
    • 市场趋势
    • 市场预测

第 10 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场趋势
    • 市场细分：按国家/地区
    • 市场预测

第 11 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 12 章：价值链分析

第 13 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 14 章：价格分析

第15章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Abbott Laboratories
    • AstraZeneca plc
    • CSL Limited
    • Daiichi Sankyo Company Limited
    • Emergent BioSolutions Inc.
    • F. Hoffmann-La Roche AG
    • Gamma Vaccines Pty Ltd
    • GlaxoSmithKline plc
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi
    • SINOVAC
Product Code: SR112024A4206

The global influenza vaccine market size reached US$ 6.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 12.5 Billion by 2032, exhibiting a growth rate (CAGR) of 6.9% during 2024-2032. The launch of numerous favorable initiatives by government bodies promoting vaccination programs, the rising prevalence of influenza and seasonal outbreaks, and the introduction of more effective and broadly protective influenza vaccines are some of the key factors driving the market globally.

Global Influenza Vaccine Market Analysis:

Major Market Drivers: One of the primary influenza vaccine market drivers is the growing initiatives launched by healthcare organizations to increase public awareness regarding the importance of influenza vaccinations. These agencies are also organizing health education campaigns, which are propelling the market growth. Furthermore, government bodies across countries are providing subsidies and free vaccinations for priority age groups, such as elderly individuals, healthcare workers, and children, which, in turn, is improving access to vaccines.

Key Market Trends: One of the primary influenza vaccine market trends is the rising investment by key players in the production and distribution of quadrivalent vaccines. In addition, the introduction of novel technologies, such as recombinant and cell-based approaches, is expected to bolster the influenza vaccine market demand over the forecasted period.

Geographical Trend: According to the report, North America holds the largest regional market for influenza vaccines. The increasing focus of healthcare authorities to prioritize vaccination programs and campaigns is driving the regional market. Furthermore, well-established healthcare infrastructures in North America and extensive investments in R&D activities are also acting as significant growth-inducing factors.

Competitive Landscape: Some of the prominent companies in the influenza vaccine market include Abbott Laboratories, AstraZeneca plc, CSL Limited, Daiichi Sankyo Company Limited, Emergent BioSolutions Inc., F. Hoffmann-La Roche AG, Gamma Vaccines Pty Ltd, GlaxoSmithKline plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi, and SINOVAC, among many others.

Challenges and Opportunities: One of the key challenges in the influenza vaccine market outlook is complex regulatory approval processes that can negatively impact the distribution of vaccines. In addition to this, the inflating need for scaling up production and ensuring efficacy and safety across various age groups is further hindering the global market. However, the rising efforts from government bodies and public healthcare organizations to ensure that influenza vaccines are accessible, effective, and accepted by individuals will continue to augment the influenza vaccine market growth in the coming years.

Global Influenza Vaccine Market Trends:

Increasing Seasonal Influenza Outbreaks and Pandemics

The rising cases of seasonal influenza are elevating the hospitalization rates. For example, according to the Statista Research report, published on December 6, 2023, there were 31 million cases of influenza in the United States during the 2022-2023 flu season. Moreover, there were 4,977 number of deaths caused by influenza during the 2021-2022 flu season. In addition to this, a large part of the population in the United States failed to get vaccinated. In 2021-2022, only 37 % of those aged 18 to 49 years received a flu vaccination, which was much lower as compared to children and the elderly. As such, the elevating focus among healthcare organizations on highlighting the importance of influenza vaccinations is bolstering the market growth. For instance, in February 2023, the World Health Organization (WHO) announced the recommendations for the viral composition of influenza vaccines for the 2023-2024 influenza season. The announcement was made at an information session at the end of a 4-day meeting on the composition of influenza virus vaccines.

The Rising Awareness Towards Influenza Vaccination

The growing prevalence of seasonal influenza is primarily bolstering the market growth. For example, the global flu data that was published in February 2022 mentioned that an estimated 1 billion individuals worldwide were infected by seasonal influenza. In line with this, the report also stated that out of those 1 billion, about 3 to 5 million people had a severe case of flu every year. Furthermore, according to the data published by WHO in December 2022, 5%-15% of the population was affected by influenza in the European region. Similarly, the Plos One Journal article published in July 2021 mentioned that approximately 5%-10% and 20%-30% of new cases of influenza infections occurred among children and adults annually. The elevating cases of the influenza virus are increasing awareness among individuals towards influenza vaccination, which is providing a positive outlook to the overall market growth. Besides this, healthcare organizations are launching campaigns to provide information regarding the benefits of immunization, thereby driving the demand for influenza vaccines. For example, a healthcare survey conducted in June 2022 by Sanofi reported that pharmacists and physicians recommended Centers for Disease Control and Prevention (CDC) to provide vaccines like Fluzone high-dose quadrivalent, for people who're 65 and older, for the treatment of influenza. The growing inclination among individuals of all age groups will continue to propel the influenza vaccine market share over the forecasted period.

The Growing Support from Government Bodies

Government bodies across the globe are collaborating with key companies to support R&D activities related to the development of influenza vaccines. As per the influenza vaccine market statistics, in September 2021, the Centers for Disease Control and Prevention (CDC) entered a broad inter-agency partnership coordinated by the Biomedical Advanced Research and Development Authority (BARDA) that supported the advanced development of novel influenza vaccines. Furthermore, government authorities are enhancing and easing the process of regulatory approvals, which is positively influencing the influenza vaccine market growth. For example, in July 2022, the United States FDA approved the request of GlaxoSmithKline for the Fluarix, which is a quadrivalent vaccine. In line with this, the government is also investing in clinical trials and R&D activities related to the development of influenza vaccinations. For instance, in March 2022, the government bodies in Australia invested more than US$ 100 Million in the seasonal influenza vaccine to protect individuals at risk. Additionally, major healthcare companies are investing extensively in the introduction of advanced therapy in the form of vaccines. This, in turn, is bolstering the future of influenza vaccine market.

Influenza Vaccine Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global influenza vaccine market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on vaccine type, technology, age group and route of administration.

Breakup by Vaccine Type:

Quadrivalent

Trivalent

Quadrivalent represents the most popular type of influenza vaccine

The report has provided a detailed breakup and analysis of the market based on the vaccine type. This includes quadrivalent and trivalent. According to the report, quadrivalent represented the largest segment.

Quadrivalent influenza vaccines are specifically designed to protect against four flu viruses, namely two influenza A viruses and two influenza B viruses. The quadrivalent segment holds a significant share of the influenza vaccine market, owing to its efficacy against viral infections, cost-effectiveness, and easy availability in clinics and hospitals. In addition to this, the fast product approvals for the quadrivalent type of vaccine are also fueling the market growth. For example, in July 2022, the United States FDA approved the request of GlaxoSmithKline for the Fluarix, which is a quadrivalent vaccine. The Fluarix quadrivalent vaccine provides active immunization to prevent disease caused by the influenza A subtype virus and type B virus. Furthermore, key companies are investing in vaccine facilities to elevate the production processes, thereby driving the global market for influenza vaccine. For example, in April 2021, Sanofi invested over € 600 million to build a new vaccine facility in Toronto to increase its supply of influenza vaccines in the United States, Canada, and Europe. The new facility developed quadrivalent influenza vaccines and served its customers with effective vaccinations.

Breakup by Technology:

Egg-based

Cell-based

Egg-based holds the largest share in the market

A detailed breakup and analysis of the market based on the technology has also been provided in the report. This includes egg-based and cell-based. According to the report, egg-based accounted for the largest market share.

Egg-based technology refers to one of the conventional methods utilized for vaccine production, wherein the influenza virus strains are grown in chicken eggs before being processed and harvested for vaccine formulation. Moreover, the egg-based method has been extensively adopted, owing to its established safety, scalability, cost-effectiveness, etc. For example, in February 2024, the WHO announced recommendations for the viral composition of influenza vaccines for the 2024-2025 influenza season in the northern hemisphere. The egg-based vaccines that are recommended include an A/Victoria/4897/2022 (H1N1)pdm09-like virus, an A/Thailand/8/2022 (H3N2)-like virus, and a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.

Breakup by Age Group:

Pediatric

Adult

Pediatric dominates the market

A detailed breakup and analysis of the market based on the age group has also been provided in the report. This includes pediatric and adult. According to the report, pediatric accounted for the largest market share.

Pediatric vaccines are specifically formulated to enhance the immune systems of children, especially those under the age of five, who are more susceptible to severe flu-related complications. These vaccinations aid in ensuring adequate protection against the disease. Consequently, healthcare providers, government bodies, and parents are recognizing the importance of pediatric influenza vaccination, leading to the escalating demand for pediatric flu vaccines.

Breakup by Route of Administration:

Injection

Nasal Spray

A detailed breakup and analysis of the market based on the route of administration has also been provided in the report. This includes injection and nasal spray.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance in the market

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest regional market for influenza vaccines.

In North America, the growing prevalence of the influenza virus is propelling the regional market. According to the CDC data, nearly 150,865 influenza-positive cases were reported in December 2022, among which 149,704 cases were influenza A and 1,61 influenza B virus types. In line with this, in December 2022, the Public Health Agency of Canada mentioned that nearly 34,413 influenza cases were reported in Canada from August 2022 to December 2022. Such increased occurrence of influenza cases among the population across North America is expected to drive the need for influenza vaccines. For instance, in June 2021, NIH launched the clinical trials of FluMos-v1, a vaccine candidate in the United States. This vaccine stimulates antibodies against multiple influenza virus strains by displaying part of the influenza virus proteins.

Competitive Landscape:

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the influenza vaccine top companies are listed below:

Abbott Laboratories

AstraZeneca plc

CSL Limited

Daiichi Sankyo Company Limited

Emergent BioSolutions Inc.

F. Hoffmann-La Roche AG

Gamma Vaccines Pty Ltd

GlaxoSmithKline plc

Merck & Co. Inc.

Novartis AG

Pfizer Inc.

Sanofi

SINOVAC

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Global Influenza Vaccine Market News:

March 2024: Osivax, a biopharmaceutical company, announced that all participants have completed their final visit in the Phase 2a clinical trial (NCT05734040) evaluating OVX836, which was a broad-spectrum influenza A vaccine and quadrivalent influenza vaccines (QIVs) candidate.

March 2024: Ahmedabad-based pharmaceutical company, Cadila Pharmaceuticals, announced the launch of a new influenza vaccine called Cadiflu Tetra.

February 2024: The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of two vaccines for active immunization against the H5N1 subtype of the influenza A virus, which causes avian influenza or bird flu.

October 2023: Mylab in Pune and Serum Institute of India have launched Nasovac S4, India's first needle-free nasal influenza vaccine.

Key Questions Answered in This Report

  • 1. What was the size of the global influenza vaccine market in 2023?
  • 2. What is the expected growth rate of the global influenza vaccine market during 2024-2032?
  • 3. What are the key factors driving the global influenza vaccine market?
  • 4. What are the key factors driving the global influenza vaccine market?
  • 5. What has been the impact of COVID-19 on the global influenza vaccine market?
  • 6. What is the breakup of the global influenza vaccine market based on the vaccine type?
  • 7. What is the breakup of the global influenza vaccine market based on the technology?
  • 8. What is the breakup of the global influenza vaccine market based on the age group?
  • 9. What are the key regions in the global influenza vaccine market?
  • 10. Who are the key players/companies in the global influenza vaccine market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Influenza Vaccine Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Vaccine Type

  • 6.1 Quadrivalent
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Trivalent
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Technology

  • 7.1 Egg-based
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Cell-based
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Age Group

  • 8.1 Pediatric
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Adult
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Route of Administration

  • 9.1 Injection
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Nasal Spray
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbott Laboratories
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 AstraZeneca plc
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 CSL Limited
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Daiichi Sankyo Company Limited
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Emergent BioSolutions Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 F. Hoffmann-La Roche AG
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 SWOT Analysis
    • 15.3.7 Gamma Vaccines Pty Ltd
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
    • 15.3.8 GlaxoSmithKline plc
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Merck & Co. Inc.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Novartis AG
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Pfizer Inc.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Sanofi
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis
    • 15.3.13 SINOVAC
      • 15.3.13.1 Company Overview
      • 15.3.13.2 Product Portfolio
      • 15.3.13.3 Financials

List of Figures

  • Figure 1: Global: Influenza Vaccine Market: Major Drivers and Challenges
  • Figure 2: Global: Influenza Vaccine Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Influenza Vaccine Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Influenza Vaccine Market: Breakup by Vaccine Type (in %), 2023
  • Figure 5: Global: Influenza Vaccine Market: Breakup by Technology (in %), 2023
  • Figure 6: Global: Influenza Vaccine Market: Breakup by Age Group (in %), 2023
  • Figure 7: Global: Influenza Vaccine Market: Breakup by Route of Administration (in %), 2023
  • Figure 8: Global: Influenza Vaccine Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Influenza Vaccine (Quadrivalent) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Influenza Vaccine (Quadrivalent) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Influenza Vaccine (Trivalent) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Influenza Vaccine (Trivalent) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Influenza Vaccine (Egg-based) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Influenza Vaccine (Egg-based) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Influenza Vaccine (Cell-based) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Influenza Vaccine (Cell-based) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Influenza Vaccine (Pediatric) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Influenza Vaccine (Pediatric) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Influenza Vaccine (Adult) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Influenza Vaccine (Adult) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Influenza Vaccine (Injection) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Influenza Vaccine (Injection) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Influenza Vaccine (Nasal Spray) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Influenza Vaccine (Nasal Spray) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: North America: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: North America: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: United States: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: United States: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Canada: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Canada: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Asia-Pacific: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Asia-Pacific: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: China: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: China: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Japan: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Japan: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: India: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: India: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: South Korea: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: South Korea: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Australia: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Australia: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Indonesia: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Indonesia: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Others: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Others: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Europe: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Europe: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Germany: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Germany: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: France: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: France: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: United Kingdom: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: United Kingdom: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Italy: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Italy: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Spain: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Spain: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Russia: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Russia: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Others: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Others: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Latin America: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Latin America: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Brazil: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Brazil: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Mexico: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Mexico: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Others: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Others: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Middle East and Africa: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Middle East and Africa: Influenza Vaccine Market: Breakup by Country (in %), 2023
  • Figure 73: Middle East and Africa: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Global: Influenza Vaccine Industry: SWOT Analysis
  • Figure 75: Global: Influenza Vaccine Industry: Value Chain Analysis
  • Figure 76: Global: Influenza Vaccine Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Influenza Vaccine Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Influenza Vaccine Market Forecast: Breakup by Vaccine Type (in Million US$), 2024-2032
  • Table 3: Global: Influenza Vaccine Market Forecast: Breakup by Technology (in Million US$), 2024-2032
  • Table 4: Global: Influenza Vaccine Market Forecast: Breakup by Age Group (in Million US$), 2024-2032
  • Table 5: Global: Influenza Vaccine Market Forecast: Breakup by Route of Administration (in Million US$), 2024-2032
  • Table 6: Global: Influenza Vaccine Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Influenza Vaccine Market: Competitive Structure
  • Table 8: Global: Influenza Vaccine Market: Key Players